方法：选取2011-02/2013-09间在我院接受治疗的46例晚期NVG患者。分为两组，每组23例，A组为观察组，行玻璃体腔注射bevacizumab联合复合式小梁切除术，B组为对照组，给睫状体冷凝术治疗。术后对两组患者视力、眼压、虹膜新生血管、术后并发症进行对比观察，随访12mo。

结果：两组术后眼压均较术前下降，A组术后眼压水平低于B组，差异有统计学意义(P<0. 05)，A组治疗成功19例(83%)， B组治疗成功12例(52%)，差异有统计学意义(χ²=4.847，P=0.028)。

结论：玻璃体腔注射bevacizumab联合复合式小梁切除术治疗NVG能够有效控制眼压，成功率较高。

METHODS: Totally 46 patients with advanced NVG from February 2011 to September 2013 in our hospital were selected and divided into observation group(group A)and control group(group B), 23 cases in each group. Patients in group A were treated with intravitreal injection of bevacizumab combined with complex trabeculectomy. Patients in group B were treated with cyclocryotherapy. The visual acuity, intraocular pressure(IOP), degeneration of iris neovascularization and postoperative complications of the two groups were observed. All the patients were followed up for 12mo.

RESULTS: The postoperative IOP was decreased significantly compared with preoperative in the two groups, and the IOP level of group A was lower than that of group B, the difference was statistically significant(P<0.05). Nineteen cases(83%)were treated successfully in group A, and 12 cases(52%)in group B, the difference was statistically significant(χ²=4.847, P=0.028).

CONCLUSION: Intravitreal injection of bevacizumab combined with complex trabeculectomy for neovascular glaucoma can effectively control IOP, and has higher successful rate.